Pfizer Aktie

20,78 EUR -0,09 EUR -0,41 %

08:00:50

STU

23,98 USD -0,02 USD -0,06 %

nachbörslich01:35:56

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.120,80 Mrd. EUR

KGV18,83Div. Rendite6,37%

WKN852009

ISINUS7170811035

SymbolPFE

Pfizer Aktien News

Sortieren:Datum Meistgelesen

24.07.24BusinesswirePfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate

11.07.24BusinesswirePfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron

09.07.24BusinesswirePfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development

01.07.24BusinesswireCyrus Taraporevala Elected to Pfizer’s Board of Directors

27.06.24BusinesswirePfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union

26.06.24BusinesswirePfizer Declares Third-Quarter 2024 Dividend

18.06.24BusinesswirePfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts

14.06.24BusinesswireELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma

12.06.24BusinesswirePfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy

03.06.24BusinesswirePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

01.06.24BusinesswirePfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/?Refractory Diffuse Large B-cell Lymphoma (DLBCL)

31.05.24BusinesswirePfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression

13.05.24PR NewswireAstellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting

06.05.24BusinesswirePfizer Announces New Chief Strategy and Innovation Officer

01.05.24BusinesswirePfizer Reports First-Quarter 2024 Results

30.04.24BusinesswireFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer

29.04.24BusinesswirePfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting

26.04.24BusinesswireU.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B

24.04.24BusinesswirePfizer Declares Second-Quarter 2024 Dividend

22.04.24BusinesswireEuropean Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options

11.04.24BusinesswirePfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25

09.04.24BusinesswirePfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease

08.04.24PR NewswireALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager

20.03.24BusinesswirePfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts

13.03.24BusinesswireEuropean Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease

12.03.24BusinesswirePfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/?Refractory Diffuse Large B-cell Lymphoma (DLBCL)

05.03.24BusinesswirePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

29.02.24BusinesswirePfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth

29.02.24BusinesswirePfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults

26.02.24BusinesswirePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

19.02.24BusinesswireEuropean Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

15.02.24BusinesswirePfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day

05.02.24BusinesswireBreaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities

30.01.24BusinesswirePfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance

26.01.24BusinesswireEuropean Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

26.01.24PR NewswireEuropean Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

10.01.24BusinesswirePfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

09.01.24BusinesswireTIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer

08.01.24BusinesswireEuropean Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

02.01.24BusinesswirePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer News

Pfizer News: auf dieser Seite finden Sie alle Pfizer News und Nachrichten zur Pfizer Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Pfizer News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Pfizer News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.